Back to Results
Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects with Advanced Solid Tumors
Colorectal Cancer - Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects with Advanced Solid Tumors
||Wasif Saif, MD
||Jennifer Caplain, RN
The purpose of this study is see how safe IM-3C5 is when given to subjects and to determine the best administering dose. We want to see what effects, good and/or bad, the study drug has on you and your tumor.
- Subject has a histologic or cytologic confirmation of cancer
- Subjects with advanced/metastatic colorectal cancer that is refractory to standard therapy
- Subject has lymphoma or leukemia
- Subject has undergone a major surgical procedure, radiation therapy, open biopsy, radiofrequency ablation, or has experienced a significant traumatic injury within 28 days prior to enrollment
- Subject has known or suspected brain or leptomeningeal metastases
All subjects in the study will receive IMC-3C5 through a needle in their vein over 90 minutes. Subjects will be dosed every week. Subjects with colorectal cancer, will receive 30 mg/kg once weekly. All cycles will consist of 4 weekly doses of the study drug and will last 4 weeks. The study requires physical exams, blood work, ECG, and other exams as needed.